Dr. Jonathan Isaac Macy, MD

Dr. Macy practices at 90210 Surgery Medical Center in Beverly Hills, California.

Dr. Macy's NPI, 1922020205, was assigned on July 24, 2006. Dr. Macy graduated from Boston University School Of Medicine in 1976. Dr. Macy holds California license G35551.

Dr. Macy's primary practice is 90210 Surgery Medical Center, at 450 North Roxbury Drive, Suite #600, Beverly Hills, CA 90210. The practice phone is (310) 651-2280.

Dr. Macy's primary practice is 90210 Surgery Medical Center in Beverly Hills, California. Dmand AI also links Dr. Macy to 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Macy practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Macy's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Macy is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Macy is licensed in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Macy treats.

CMS data shows 4,469 Medicare services from Dr. Macy across 20 procedure codes in 2024, for 1,274 Medicare patients. Medicare paid $347,874 for them.

CMS counts 1,274 Medicare patients who saw Dr. Macy in 2024. The largest group is 75 to 84, with 546 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.24, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Macy's median patient age at 67, with 57% women.

In 2024, Dr. Macy wrote 2,135 Medicare Part D claims for 583 patients. 54% of them were for generic drugs. CMS names the drug for 2,003 of them, across 24 drugs with 11 or more claims each, at $191,594 in total drug cost. In 2023, CMS named 2,160 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Macy for performance year 2024, reported individually. Dr. Macy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Macy as offering telehealth. CMS counts 147 procedures of cataract surgery by Dr. Macy, more than 80% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Macy in 2014. Dr. Macy's most frequent co-authors are Christopher R. Croasdale, MD, Robert Scott Feder, MD and Sarkis H. Soukiasian, MD.

Dmand AI links Dr. Macy to 18 clinical trials, 8 of them phase 3 studies. Conditions studied include Glaucoma, Open-Angle, Glaucoma and Conjunctivitis, Bacterial. Bausch & Lomb Incorporated sponsors the most, 3. Open Payments lists research payments to Dr. Macy that name 1 trial.

CMS Open Payments shows 177 general payments to Dr. Macy from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Alcon Laboratories Inc paid the most, $1,399. It also lists 11 research payments totaling $61,520 from 2016 to 2020, naming 1 clinical trial.

Dmand AI lists 7 awards for Dr. Macy, most recently ESGR Patriot Award in 2011.

Dr. Macy graduated from Boston University School Of Medicine in 1976. Dr. Macy is a member of AAO.

Dr. Macy is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.